Search

Search results

59 results found

Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.

Prete, Alessandro, Agnes S Lo, Peter M Sadow, Swati S Bhasin, Zeus A Antonello, Danica M Vodopivec, Soumya Ullas, et al. 2018. “Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.”. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24 (23): 6078-97.

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

Duquette, Mark, Peter M Sadow, Amjad Husain, Jennifer N Sims, Zeus A Antonello, Andrew H Fischer, Chen Song, et al. 2015. “Metastasis-Associated MCL1 and P16 Copy Number Alterations Dictate Resistance to Vemurafenib in a BRAFV600E Patient-Derived Papillary Thyroid Carcinoma Preclinical Model.”. Oncotarget 6 (40): 42445-67.

Research

Our lab is developing independent research program in the CVBR at the BIDMC/HMS, focused on preclinical models of human thyroid cancer with an emphasis on mechanisms of metastatic networks, new models of in vitro angiogenesis, tumor microenvironment, and metabolic regulations, using and dissecting...